The FDA has set April 28th as the date when an advisory committee will make its recommendation on Vertex's telaprevir. Telaprevir is used in combination therapy for the treatment of hepatitis C.
If Vertex gets by the advisory committe (as expected), the final FDA approval should come down in its favor by May 23rd. Analysts have projected telaprevir as a drug with $1 billion+ potential and it is being eagerly watched by company officials, analysts and patients alike.
Posted by Bruce Lehr March 18th 2011.